Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies.

Journal: Cancer Cell

Published: 2020-08-19

DOI: 10.1016/j.ccell.2020.08.001

Affiliations: 16

Authors: 22

Go to article
Institutions Share
MOE Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Tsinghua, China 0.19
Tsinghua University, China 0.19
Sun Yat-sen University (SYSU), China 0.09
Xijing Hospital, China 0.09
Zhuhai Yufan Biotechnologies Co., Ltd., China 0.05
Xi'an Yufan Biotechnologies Co., Ltd., China 0.05
Guang An Men Hospital (GAM), CACMS, China 0.05
The Third Xiangya Hospital, CSU, China 0.05
Guangzhou General Hospital of Guangzhou Military Command of PLA, China 0.05
Health Sciences, Pitt, United States of America (USA) 0.05
Lanzhou Institute of Husbandry and Pharmaceutical Sciences (LIHPS), CAAS, China 0.05
Beijing Chaoyang Hospital, Capital Medical University, China 0.05
First Affiliated Hospital, ZJU, China 0.05
Beijing Obstetrics and Gynecology Hospital, Capital Medical University, China 0.02
Peking University-Tsinghua University-National Institute of Biological Sciences Joint Graduate Program (PTN), China 0.02

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER